Community-acquired bacterial pneumonia (CABP) is a commonly occurring serious infection that requires systemic antibiotic therapy and is associated with substantial morbidity, mortality, and considerable healthcare costs.It is the leading cause of death from infectious diseases MedDRA version: 19.0 Level: LLT Classification code 10004051 Term: Bacterial pneumonia, unspecified System Organ Class: 100000004862
Conditions
Interventions
Product Name: lefamulin
Product Code: BC-3781
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Lefamulin
CAS Number: 1061337-51-6
Current Sponsor code: BC-3781
Other descriptive name: Lefa
Sponsors
Nabriva Therapeutics AG
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Be male or female = 18 years of age. 2. Provide written informed consent and be willing and able to adhere to the study-specified procedures and restrictions. NOTE: Consent may be provided by the subject’s legally authorized representative in accordance with local regulations. 3. Have an acute illness (= 7 days duration) with at least 3 of the following symptoms consistent with a lower respiratory tract infection (new or worsening): • Dyspnea. • New or increased cough. • Purulent sputum production. • Chest pain due to pneumonia. 4. Have at least 2 of the following vital sign abnormalities: • Fever (body temperature > 38.0 °C (100.4 °F) measured orally or equivalent temperature from an alternate body site) or hypothermia (body temperature 100 beats/min). • Tachypnea (respiratory rate > 20 breaths/min). 5. Have at least 1 other clinical sign or laboratory finding of CABP: • Hypoxemia (i.e., O2 saturation 10 000 cells/mm3 or 15 % immature neutrophils (bands) regardless of total WBC count. 6. Have radiographically-documented pneumonia within 48 hours before enrollment (i.e., infiltrates in a lobar or multilobar distribution or diffuse opacities on chest x-ray consistent with acute bacterial pneumonia). NOTE: if a chest computed tomography scan has been performed within 48 hours of enrollment and demonstrates findings consistent with pneumonia, it can be used in place of a chest x-ray. 7. Have a Pneumonia Outcomes Research Team (PORT) Risk Class of II, III, or IV and be an appropriate candidate for oral antibiotic therapy as treatment for the current episode of CABP. 8. If female, meets the following criteria: • Surgically sterile or = 2 years postmenopausal, or if of childbearing potential (including being =65 years) yes F.1.3.1 Number of s
Exclusion criteria
Exclusion criteria: 1. Have received more than a single dose of a short-acting oral or IV antibacterial for CABP within 72 hours before randomization 2. Require concomitant systemic antibacterial therapy potentially effective against CABP pathogens 3. Have been hospitalized for 2 or more days within 90 days prior to the onset of symptoms or have resided in a nursing home or long-term healthcare facility within 30 days prior to the onset of symptoms. 4. Have confirmed or suspected CABP caused by a pathogen known to be resistant to any of the study drugs (e.g., MRSA, Pseudomonas aeruginosa, any pathogen of the Enterobacteriaceae Family) or attributable to etiologies other than community-acquired bacterial pathogens (e.g., ventilator-associated pneumonia, hospital-acquired bacterial pneumonia, bacterial aspiration pneumonia, Pneumocystis jiroveci pneumonia or other fungal pneumonia, viral or mycobacterial infection of the lung). 5. Have a noninfectious cause of pulmonary infiltrates (e.g., pulmonary embolism, chemical pneumonitis from aspiration, hypersensitivity pneumonia, congestive heart failure, bronchial obstruction, lung cancer, cystic fibrosis). 6. Have confirmed or suspected pleural empyema (does not include sterile parapneumonic effusions). 7. Have or be at risk for major cardiac events or dysfunction including, but not limited to, the following: • Known prolonged QT interval or family history of long QT syndrome • Clinically significant hypokalemia which has not been treated prior to randomization • Clinically unstable cardiac disease, including: unstable atrial fibrillation, symptomatic bradycardia, unstable congestive heart failure, active myocardial ischemia, or indwelling pacemaker • Complete left bundle branch block • Receipt within 7 days before enrollment of Class IA or Class III anti-arrhythmic medication or, in the opinion of the Investigator, subject may require such medication during the study. (Class 1A: Quinidine, Procainamide, Disopyramide; Class III: Amiodarone, Dofetilide, Ibutilide, Sotalol) • Receipt within 7 days before enrollment of medication that has the potential of prolonging the QT interval or, in the opinion of the Investigator, subject may require such medication during the study 8. Be receiving a strong p-glycoprotein inhibitor or a strong CYP3A inducer or inhibitor 9. Have a history of tendon disease/disorder, myasthenia gravis, or known or suspected central nervous system (CNS) disorders (severe cerebrovascular arteriosclerosis, epilepsy, or other risk factors that may predispose to seizures). 10. Have a history of any hypersensitivity or allergic reaction to any fluoroquinolone, or any drug in the pleuromutilin class (i.e., retapamulin). 11. Have severely impaired renal function, defined as estimated creatinine clearance (CrCl) = 30 mL/min as calculated by the Cockcroft-Gault formula. 12. Have evidence of significant hepatic, hematologic, or immunologic disease including any of the following: • Known acute hepatitis, including acute viral hepatitis. • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level > 5 times the upper limit of normal (ULN), • Total bilirubin > 3 times the ULN (unless known Gilbert’s disease). • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level > 3 times the upper limit of normal (ULN) and total bilirubin > 2 times the ULN. • History of cirrhosis of the liver. • Manifestation of end-stage liver disease, such as ascites or hepat
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Primary Objectives • Demonstrate the non-inferiority (NI) of lefamulin versus comparator with respect to the Early Clinical Response (96 ± 24 hours after the first dose of study drug) in the Intent-to-Treat (ITT) Analysis Set (FDA endpoint). • Demonstrate the NI of lefamulin versus comparator with respect to the Investigator’s Assessment of Clinical Response at Test of Cure (TOC) (i.e., 5-10 days after the last dose of study drug) in the modified-ITT (mITT) and Clinically Evaluable at TOC (CE-TOC) Analysis Sets (EMA endpoint).;Secondary Objective: Secondary Objectives • Evaluate the Early Clinical Response in the Microbiological Intent-to-Treat (microITT) Analysis Set. • Evaluate the Investigator’s Assessment of Clinical Response at TOC in the microITT and Microbiologically Evaluable at TOC (ME-TOC) Analysis Sets. • Evaluate the By-Pathogen Microbiologic Response at TOC in the microITT and ME-TOC Analysis Sets. • Evaluate the safety and tolerability of lefamulin versus comparator in the Safety Analysis Set. • Evaluate 28 day all-cause mortality in the ITT Analysis Set.;Primary end point(s): Demonstrate the non-inferiority (NI) of lefamulin versus comparator with respect to the Early Clinical Response (96 ± 24 hours after the first dose of study drug) in the Intent-to-Treat (ITT) Analysis Set (FDA endpoint). • Demonstrate the NI of lefamulin versus comparator with respect to the Investigator’s Assessment of Clinical Response at Test of Cure (TOC) (i.e., 5-10 days after the last dose of study drug) in the modified-ITT (mITT) and Clinically Evaluable at TOC (CE-TOC) Analysis Sets (EMA endpoint).;Timepoint(s) of evaluation of this end point: The EMA supports assessment of clinical response by Investigators at a test of cure (TOC) visit, while the FDA adopted assessment of clinical signs and symptoms of CABP on Days 3 to 5 as the recommended primary endpoint. FDA endpoint - 96 hours +/- 24 hours EMA endpoint - 2 days after the last dose of study drug | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Please use the following for secondary endpoints - the time of evaluation is in parentheses after the endpoint: Secondary Objectives - Evaluate the Early Clinical Response in the Microbiological Intent-to-Treat (microITT) Analysis Set. (96 ± 24 hours after the first dose of study drug) - Evaluate the Investigator’s Assessment of Clinical Response at TOC in the microITT and Microbiologically Evaluable at TOC (ME-TOC) Analysis Sets. (5-10 days after the last dose of study drug) - Evaluate the By-Pathogen Microbiologic Response at TOC in the microITT and ME-TOC Analysis Sets. (5-10 days after the last dose of study drug) -Evaluate the safety and tolerability of lefamulin versus comparator in the Safety Analysis Set. -Evaluate 28?day all-cause mortality in the ITT Analysis Set (Day 28) ;Timepoint(s) of evaluation of this end point: Days 3 – 5, Day s 5 – 10 and Day 28 | — |
Countries
Argentina, Brazil, Bulgaria, Chile, Georgia, Hungary, Korea, Republic of, Latvia, Mexico, Peru, Philippines, Poland, Romania, Russian Federation, Serbia, South Africa, Spain, Taiwan, Ukraine, United States
Contacts
Public ContactClinical Trial Information
Nabriva Therapeutics AG
Outcome results
None listed